E. Williams

511 total citations
22 papers, 375 citations indexed

About

E. Williams is a scholar working on Pulmonary and Respiratory Medicine, Pharmacology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, E. Williams has authored 22 papers receiving a total of 375 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 2 papers in Pharmacology and 2 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in E. Williams's work include Cystic Fibrosis Research Advances (17 papers), Antibiotics Pharmacokinetics and Efficacy (2 papers) and Tracheal and airway disorders (1 paper). E. Williams is often cited by papers focused on Cystic Fibrosis Research Advances (17 papers), Antibiotics Pharmacokinetics and Efficacy (2 papers) and Tracheal and airway disorders (1 paper). E. Williams collaborates with scholars based in Australia, Ireland and United States. E. Williams's co-authors include John Wilson, Brenda Button, James Jacobs, D. Keating, Tom Kotsimbos, Susan Poole, Johnson George, Roger L. Nation, Michelle P. McIntosh and Christopher J. H. Porter and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Antimicrobial Agents and Chemotherapy.

In The Last Decade

E. Williams

22 papers receiving 372 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
E. Williams Australia 8 239 101 76 76 35 22 375
Craig Lapin United States 10 194 0.8× 67 0.7× 82 1.1× 84 1.1× 24 0.7× 14 313
Mairi Ziaka Switzerland 10 84 0.4× 56 0.6× 39 0.5× 68 0.9× 43 1.2× 36 345
P. Vic France 9 202 0.8× 68 0.7× 83 1.1× 88 1.2× 22 0.6× 30 360
Alan B Osher United States 10 322 1.3× 17 0.2× 22 0.3× 35 0.5× 25 0.7× 15 402
Chris M. Parker Canada 7 243 1.0× 55 0.5× 18 0.2× 81 1.1× 16 0.5× 10 374
Ti Yin Taiwan 14 68 0.3× 64 0.6× 19 0.3× 49 0.6× 38 1.1× 27 509
W Bakker Netherlands 10 302 1.3× 90 0.9× 135 1.8× 132 1.7× 11 0.3× 16 401
Alexandre Charmillon France 10 45 0.2× 53 0.5× 143 1.9× 114 1.5× 21 0.6× 28 364
R. Jódar Spain 6 56 0.2× 106 1.0× 68 0.9× 82 1.1× 14 0.4× 12 207
Elsa Jozefowicz France 10 211 0.9× 52 0.5× 18 0.2× 232 3.1× 64 1.8× 11 511

Countries citing papers authored by E. Williams

Since Specialization
Citations

This map shows the geographic impact of E. Williams's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Williams with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Williams more than expected).

Fields of papers citing papers by E. Williams

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Williams. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Williams. The network helps show where E. Williams may publish in the future.

Co-authorship network of co-authors of E. Williams

This figure shows the co-authorship network connecting the top 25 collaborators of E. Williams. A scholar is included among the top collaborators of E. Williams based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Williams. E. Williams is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Spoletini, Giulia, K. Pollard, N. Shaw, et al.. (2022). Dose adjustments of Elexacaftor/Tezacaftor/Ivacaftor in response to mental health side effects in adults with cystic fibrosis. Journal of Cystic Fibrosis. 21(6). 1061–1065. 59 indexed citations
2.
Williams, E., Brenda Button, Toby Winton‐Brown, et al.. (2022). Cognitive Function in Cystic Fibrosis and CFTR Modulator Therapy. 1–6. 1 indexed citations
3.
Button, Brenda, Lisa M Wilson, Angela T. Burge, et al.. (2021). The AWESCORE, a patient-reported outcome measure: development, feasibility, reliability, validity and responsiveness for adults with cystic fibrosis. ERJ Open Research. 7(3). 120–2021. 4 indexed citations
4.
5.
Keating, D., E. Williams, Eldho Paul, et al.. (2020). Lumacaftor/ivacaftor-associated health stabilisation in adults with severe cystic fibrosis. ERJ Open Research. 7(1). 203–2020. 13 indexed citations
6.
Keating, D., Lisa M Wilson, E. Williams, Tom Kotsimbos, & Joanne A. P. Wilson. (2019). P259 Ivacaftor withdrawal syndrome during a randomised placebo-controlled cross-over study. Journal of Cystic Fibrosis. 18. S130–S130. 3 indexed citations
7.
Holton, Sara, Jane Fisher, Brenda Button, E. Williams, & John Wilson. (2018). Childbearing concerns, information needs and preferences of women with cystic fibrosis: An online discussion group. Sexual & Reproductive Healthcare. 19. 31–35. 13 indexed citations
8.
9.
Wilson, Jennifer, Alexis Talbot, David Clark, et al.. (2018). IPD2.13 Treatment with ivacaftor in CF patients with the G551D mutation is associated with improvement in cognition. Journal of Cystic Fibrosis. 17. S57–S57. 1 indexed citations
10.
Keating, D., Matthew J. Ellis, Brenda Button, et al.. (2017). Improvement in exercise duration, lung function and well-being in G551D-cystic fibrosis patients: a double-blind, placebo-controlled, randomized, cross-over study with ivacaftor treatment. Clinical Science. 131(15). 2037–2045. 45 indexed citations
11.
Williams, E., Brenda Button, Audrey Tierney, et al.. (2015). ePS03.4 Patient reported adherence to ivacaftor. Journal of Cystic Fibrosis. 14. S46–S46. 5 indexed citations
12.
Keating, D., E. Williams, Brenda Button, et al.. (2015). WS14.1 Ivacaftor improves exercise capacity in patients with G551D CF gene mutations. Journal of Cystic Fibrosis. 14. S27–S27. 2 indexed citations
13.
Keating, D., E. Williams, Brenda Button, et al.. (2015). Exercise improvements in ivacaftor treated G551D cystic fibrosis patients are not solely related to FEV1 and sweat changes. PA2047–PA2047. 2 indexed citations
14.
Tierney, Audrey, E. Williams, D. Keating, et al.. (2015). ePS05.3 Ivacaftor and its effects on body composition in adults with G551D related cystic fibrosis. Journal of Cystic Fibrosis. 14. S50–S50. 4 indexed citations
15.
Li, Jian, Kashyap Patel, John Wilson, et al.. (2014). Pulmonary and Systemic Pharmacokinetics of Inhaled and Intravenous Colistin Methanesulfonate in Cystic Fibrosis Patients: Targeting Advantage of Inhalational Administration. Antimicrobial Agents and Chemotherapy. 58(5). 2570–2579. 135 indexed citations
16.
El-Masry, Sahar A., M. Braithwaite, David Clark, et al.. (2010). Adherence behaviour of adult cystic fibrosis (CF) patients to prescribed azithromycin. Journal of Cystic Fibrosis. 9. S24–S24. 3 indexed citations
17.
Meyer, Tim, Sy Ha, Dominic Yu, et al.. (2010). A randomized phase II/III trial of three weekly cisplatin based transarterial chemoembolization (TACE) versus embolization (TAE) alone for hepatocellular cancer (HCC).. Journal of Clinical Oncology. 28(15_suppl). 4025–4025. 2 indexed citations
18.
Jacobs, James & E. Williams. (1993). Algorithm to control "effect compartment" drug concentrations in pharmacokinetic model-driven drug delivery. IEEE Transactions on Biomedical Engineering. 40(10). 993–999. 28 indexed citations
19.
Jolson, Heidi M., Laura Bosco, B. Burt Gerstman, et al.. (1992). Clustering of Adverse Drug Events: Analysis of Risk Factors for Cerebellar Toxicity With High-Dose Cytarabine. JNCI Journal of the National Cancer Institute. 84(7). 500–505. 13 indexed citations
20.
Williams, E. & Brian W. Bainbridge. (1976). Mutation, repair mechanisms and transformation in the methane-utilizing bacterium, Methylococcus capsulatus. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Craig Lapin Breakdown of academic impact, for papers by Mairi Ziaka Breakdown of academic impact, for papers by P. Vic Breakdown of academic impact, for papers by Alan B Osher Breakdown of academic impact, for papers by Chris M. Parker Breakdown of academic impact, for papers by Ti Yin Breakdown of academic impact, for papers by W Bakker Breakdown of academic impact, for papers by Alexandre Charmillon Breakdown of academic impact, for papers by R. Jódar Breakdown of academic impact, for papers by Elsa Jozefowicz
Rankless by CCL
2026